David Shelton - Chemours Senior Vice President, General Counsel, Secretary

CC Stock  USD 21.53  0.73  3.51%   

President

Mr. David Charles Shelton has appointed as Senior Vice President, Corporationrationrate Secretary and General Counsel of the Company with effect on July1, 2015. In 2011, Mr. Shelton was appointed Associate General Counsel, DuPont, and was responsible for the US Commercial team the business lawyers and paralegals counseling all the DuPont business units with the exception of Agriculture. Mr. Shelton was the Commercial attorney to a variety of DuPont businesses including the Performance Materials platform, which he advised on international assignment in Geneva, and the businesses now comprising the DuPont Chemicals and Fluoroproducts business unit. Prior to that, Mr. Shelton advised the company on environmental and remediation matters as part of the environmental legal team. Mr. Shelton joined DuPont in 1996, after seven years in private practice as a litigator in Pennsylvania and New Jersey. since 2015.
Age 57
Tenure 9 years
Address 1007 Market Street, Wilmington, DE, United States, 19801
Phone302 773 1000
Webhttps://www.chemours.com

Chemours Management Efficiency

The company has Return on Asset (ROA) of 0.0397 % which means that for every $100 of assets, it generated a profit of $0.0397. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1102 %, which means that it produced $0.1102 on every 100 dollars invested by current stockholders. Chemours' management efficiency ratios could be used to measure how well Chemours manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.03. The current year's Return On Capital Employed is expected to grow to -0.02. At present, Chemours' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 703.5 M, whereas Total Assets are forecasted to decline to about 7.5 B.
Chemours Co reports 4.3 B of total liabilities with total debt to equity ratio (D/E) of 2.94, which may imply that the company relies heavily on debt financing. Chemours has a current ratio of 1.78, which is generally considered normal. Note however, debt could still be an excellent tool for Chemours to invest in growth at high rates of return.

Similar Executives

Showing other executives

PRESIDENT Age

Grant BowmanPerimeter Solutions SA
N/A
Erica McLaughlinCabot
47
Alice HeezenTrinseo SA
49
John ManningSensient Technologies
55
Nathanial WeaverH B Fuller
48
Jeffrey EmeryPerimeter Solutions SA
48
Steve MorrisSensient Technologies
60
John WillisAshland Global Holdings
59
Patrick AnderleSelect Energy Services
N/A
Jeffrey KaplanLyondellBasell Industries NV
55
Paula CooneyH B Fuller
50
Heather CampeH B Fuller
50
Andrew KennerWestlake Chemical
56
Wilbur MokAir Products and
63
Cody OrtowskiSelect Energy Services
47
John CorkreanH B Fuller
58
Ramaparasad VadlamannatiPPG Industries
61
Hobart KalksteinCabot
54
Richard OLearyInternational Flavors Fragrance
57
Sean MajorAir Products and
60
Celeste MastinH B Fuller
55
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware. Chemours operates under Specialty Chemicals classification in the United States and is traded on New York Stock Exchange. It employs 6400 people. Chemours Co (CC) is traded on New York Stock Exchange in USA. It is located in 1007 Market Street, Wilmington, DE, United States, 19801 and employs 6,200 people. Chemours is listed under Diversified Chemicals category by Fama And French industry classification.

Management Performance

Chemours Leadership Team

Elected by the shareholders, the Chemours' board of directors comprises two types of representatives: Chemours inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chemours. The board's role is to monitor Chemours' management team and ensure that shareholders' interests are well served. Chemours' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chemours' outside directors are responsible for providing unbiased perspectives on the board's policies.
Dawn Farrell, Independent Chairman of the Board
Curtis Anastasio, Independent Director
Jonathan Lock, Senior Vice President and Chief Development Officer
Amber Wellman, Chief Officer
Matthew Abbott, Vice President - Digital and Analytics Platforms Leader
Shane Hostetter, Senior CFO
David Shelton, Senior Vice President, General Counsel, Secretary
Denise Dignam, President - Advanced Performance Materials
Curtis Crawford, Independent Director
Aditya Beri, Interim Business
Mary Cranston, Independent Director
Bradley Bell, Independent Director
Sheryl Telford, Chief Sustainability Officer
Ron Charles, Senior People
Erin Kane, Independent Director
Alisha Bellezza, President - Thermal & Specialized Solutions
Joseph Martinko, President Solutions
Susan Kelliher, Senior Vice President – Human Resources and Health Services
Gerardo Calderon, President Materials
Eugene Snell, President - Titanium Technologies
Sandra Rogers, Independent Director
Kurt Bonner, Ma Relations
Kristine Wellman, General VP
Sean Keohane, Independent Director
Sameer Ralhan, Chief Financial Officer, Senior Vice President, Treasurer
Shane CPA, Senior CFO
Guillaume Pepy, Independent Director
Brandon Ontjes, Vice Relations
Camela Wisel, Chief Accounting Officer, Vice President Controller
Mark Newman, Chief Operating Officer, Senior Vice President
Edwin Sparks, President - Chemical Solutions Business, Titanium Technologies
Erich Parker, Senior Vice President of Corporate Communications and Chief Brand Officer.
Brian Shay, Interim Officer
Mark Vergnano, President, Chief Executive Officer, Director
Richard Brown, Independent Chairman of the Board
Alvenia Scarborough, Senior Vice President - Corporate Communications and Chief Brand Officer

Chemours Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chemours a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Chemours Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Diversified Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemours. If investors know Chemours will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemours listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.65)
Dividend Share
1
Earnings Share
0.5
Revenue Per Share
38.519
Quarterly Revenue Growth
0.009
The market value of Chemours is measured differently than its book value, which is the value of Chemours that is recorded on the company's balance sheet. Investors also form their own opinion of Chemours' value that differs from its market value or its book value, called intrinsic value, which is Chemours' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemours' market value can be influenced by many factors that don't directly affect Chemours' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemours' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemours is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemours' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.